



# Annual treatment with NovoPen<sup>®</sup> incl. drug and needles

## Carbon Footprint Report

September 2025 (version 1.1)

# Contents

1. Background	4
2. Methodology	5
2.1 Drug substance	6
2.2 Delivery system	6
2.3 Needles	6
3. NovoPen® 4	8
3.4 Carbon footprint NovoPen® 4	8
3.4.1 European market	8
3.4.2 US market	11
3.4.3 Japanese market	13
3.4.4 Comparison to other measurements	14
3.5 Plastic footprint NovoPen® 4	16
4. NovoPen® 5	19
4.6 Carbon footprint NovoPen® 5	19
4.6.1 European market	19
4.6.2 US market	22
4.6.3 Japanese market	24
4.6.4 Comparison to other measurements	25
4.7 Plastic footprint NovoPen® 5	27
5. NovoPen® 6	30
5.8 Carbon footprint NovoPen® 6	30
5.8.1 European market	30

5.8.2 US market	33
5.8.3 Japanese market	35
5.8.4 Comparison to other measurements	36
5.9 Plastic footprint NovoPen® 6	38
<b>6. NovoPen Echo®</b>	<b>41</b>
6.10 Carbon footprint NovoPen Echo®	41
6.10.1 European market	41
6.10.2 US market	44
6.10.3 Japanese market	46
6.10.4 Comparison to other measurements	47
6.11 Plastic footprint NovoPen Echo®	49
<b>7. NovoPen Echo® Plus</b>	<b>52</b>
7.12 Carbon footprint NovoPen Echo® Plus	52
7.12.1 European market	52
7.12.2 US market	55
7.12.3 Japanese market	57
7.12.4 Comparison to other measurements	58
7.13 Plastic footprint NovoPen Echo® Plus	60
<b>References</b>	<b>63</b>

# 1. Background


Novo Nordisk's environmental strategy, Circular for Zero, and the certified ISO14001 Environmental Management System, drive continuous improvements in our environmental performance by setting high ambitions and integrating environmental considerations into daily business activities. Here, life cycle assessment/product carbon footprint is an integrated part of our product development process.

This document presents the Product Carbon Footprint of one year treatment with the different NovoPen's® (NovoPen® 4, NovoPen® 5, NovoPen® 6, NovoPen Echo®, NovoPen Echo® Plus) in combination with a range of drug substances (API), including the use of NovoFine® needles and Penfill® cartridges, hereafter referred to as the [drug product's brand name] Penfill® NovoPen® carbon footprint, e.g. Actrapid® Penfill® NovoPen® carbon footprint. The carbon and plastic footprint of the different NovoPen's® will be presented in separate chapters.

The carbon footprint for the yearly treatment is based on full third-party verified carbon footprint reports for the different drug substances, delivery solutions (device or oral) and needles included in this report.

The data presented in this document supports marketing claims and Q&As about the product carbon footprint. The data should not be used for comparison with competitor products or for claims related to 'green' or 'environmentally friendly' products.

The carbon footprint of a product is calculated by adding the greenhouse gas emissions (in kg CO<sub>2</sub> equivalents) from different stages of the product life cycle. The product carbon footprint of one year of treatment is calculated by adding the contributions from the drug substance, the delivery system and the needle<sup>1</sup>.



The carbon footprint calculations are based on production data from 2022 and cover relevant drug substances, delivery system and needles as shown in Table 1. For each brand, the carbon footprints are calculated for the use in three major markets: Europe, the US and Japan. The calculations are made using Excel and the life cycle assessment tool *LCA for Experts*<sup>3</sup>.

Drug substance	Delivery systems**	Cartridge**	Needle**
<ul style="list-style-type: none"> <li>Insulin analogues</li> </ul>	<ul style="list-style-type: none"> <li>NovoPen® 4</li> <li>NovoPen® 5</li> <li>NovoPen® 6</li> <li>NovoPen Echo®</li> <li>NovoPen Echo® Plus</li> </ul>	<ul style="list-style-type: none"> <li>Penfill®</li> <li>Excipients* (incl.WFI)</li> </ul>	<ul style="list-style-type: none"> <li>NovoFine®</li> <li>NovoFine® Plus</li> </ul>

\*\* Including both secondary & tertiary packaging.

<sup>3</sup> Formerly GaBi.

The carbon footprint has inherent uncertainties and should be regarded as an indicative level and not as a precise measure. The uncertainties relate to the data collected from Novo Nordisk production, the data on carbon footprint for each of the processes (e.g. plastic granulate production), carbon footprint impact factors and the key assumptions (e.g. distribution patterns). Moreover, the calculations consider that Novo Nordisk sources renewable energy through certificates, which results in a lower carbon footprint than if average electricity was used.

## 2.1 Drug substance

The Defined Daily Dose (DDD) is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD for insulin analogues (aspart, degludec, detemir or human insulin) is 40 international units (IU), corresponding to a weekly dose of 280 units, according to the WHO, see Table 2.

Table 2 Overview of defined dose of drug substance for the different products.

Brand name	Frequency	Drug substance
Insulin analogue: Actrapid®, Fiasp®, Insulatard®, Levemir®, Mixtard®, NovoMix®, NovoRapid®, Ryzodeg <sup>4</sup> and Tresiba®.	Daily	40 IU aspart, degludec, detemir, human insulin or icodec

## 2.2 Delivery system

NovoPen® is a reusable pen with an assumed lifetime of 5 years.

NovoPen® is compatible with a variety of Novo Nordisk's drug products, available in a range of strengths tailored to the specific therapy area and delivered in Penfill®, see Table 3.

Table 3 Overview of drug product strength based on substance concentration and primary packaging size.

Brand name	Drug substance content	Cartridge (Penfill®) [mL]	Strength
[Insulin analogue] U100 NovoPen®	300 IU	3	100 IU/mL

Due to the physical design of the cartridge, a small volume of drug product is lost between the neck and the shoulders. The filling volume is adjusted to account for this loss with an additional 2.4% drug product volume. This has been considered as well for the estimation of the carbon footprint.

## 2.3 Needles

Novo Nordisk offers a series of needles for combination with our delivery systems. In this assessment, three different needles, namely, NovoFine®, NovoFine® Plus, and NovoFine® Plus (co-pack), are included for the EU and US markets. For the Japanese market only NovoFine® Plus is available.

<sup>4</sup> 40 IU with the distribution of 70% degludec, 30% aspart

NovoFine® Plus needles are sold in packs of 100 pcs in EU and US markets and packs of 70 pcs in JP market. NovoFine® Plus (co-pack) are assumed co-packed with one NovoPen® and 4 needles as a representative for a co-pack.

Novo Nordisk recommends discarding the needle after use. However, market research shows that many patients use the needle several times<sup>5</sup>. To reflect an average patient, the one-year treatment scenario is based on the use of one needle per day, which can be considered a conservative estimate.

---

<sup>5</sup> Roper U.S. Diabetes 2014 Patient Study. Insulin devices market. GFK, November 2014

### 3. NovoPen® 4

#### 3.4 Carbon footprint NovoPen® 4

This section presents the carbon footprints for specific treatments (assumptions described in Section 2) with NovoPen® 4 in combinations with a range on drug substances (delivered in Penfill®) and needles in the three representative markets, Europe, US and Japan. The contribution to the carbon footprints from drug substance, delivery system, cartridge and needles are shown as well as the total carbon footprint per patient per year.

To put the results into perspective, the resulting carbon footprints has been recalculated into the distance driven by an average car (see Section 3.4.4).

##### 3.4.1 European market

Table 4. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **European** market with NovoPen® 4 and NovoFine®

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 4 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.6	0.2	8.5	9.0
<b>Fiasp®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.6	0.2	8.5	8.9
<b>Insulatard®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.6	0.2	8.5	9.0
<b>Levemir®Penfill® NovoPen® 4</b>	6.9	0.4	0.1	4.5	0.2	2.6	0.2	14.3	14.8
<b>Mixtard®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.6	0.2	8.5	9.0
<b>NovoMix®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.6	0.2	8.5	8.9
<b>NovoRapid®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.6	0.2	8.5	8.9
<b>Ryzodeg®Penfill® NovoPen® 4</b>	1.8	0.4	0.1	4.5	0.2	2.6	0.2	9.2	9.7
<b>Tresiba®Penfill® NovoPen® 4</b>	2.1	0.4	0.1	4.5	0.2	2.6	0.2	9.5	10.0



Table 5. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **European** market with NovoPen® 4 and NovoFine® Plus.

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 4 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.0	0.2	8.0	8.5
<b>Fiasp®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.0	0.2	7.9	8.4
<b>Insulatard®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.0	0.2	8.0	8.5
<b>Levemir®Penfill® NovoPen® 4</b>	6.9	0.4	0.1	4.5	0.2	2.0	0.2	13.8	14.2
<b>Mixtard®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.0	0.2	8.0	8.5
<b>NovoMix®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.0	0.2	7.9	8.4
<b>NovoRapid®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.0	0.2	7.9	8.4
<b>Ryzodeg®Penfill® NovoPen® 4</b>	1.8	0.4	0.1	4.5	0.2	2.0	0.2	8.7	9.2
<b>Tresiba®Penfill® NovoPen® 4</b>	2.1	0.4	0.1	4.5	0.2	2.0	0.2	9.0	9.5

Table 6. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **European** market with NovoPen® 4 and NovoFine® Plus (co-pack).

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 4 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus (co-pack) [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.1	3.0	8.1	11.4
<b>Fiasp®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.1	3.0	8.0	11.3
<b>Insulatard®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.1	3.0	8.1	11.4
<b>Levemir®Penfill® NovoPen® 4</b>	6.9	0.4	0.1	4.5	0.2	2.1	3.0	13.8	17.2
<b>Mixtard®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.1	3.0	8.1	11.4
<b>NovoMix®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.1	3.0	8.0	11.3
<b>NovoRapid®Penfill® NovoPen® 4</b>	1.1	0.4	0.1	4.5	0.2	2.1	3.0	8.0	11.3
<b>Ryzodeg®Penfill® NovoPen® 4</b>	1.8	0.4	0.1	4.5	0.2	2.1	3.0	8.7	12.1
<b>Tresiba®Penfill® NovoPen® 4</b>	2.1	0.4	0.1	4.5	0.2	2.1	3.0	9.1	12.4

### 3.4.2 US market

Table 7. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **US** market with NovoPen® 4 and NovoFine®.

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 4 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	5.3	0.2	10.3	10.8
<b>Fiasp®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	5.3	0.2	10.2	10.7
<b>Insulatard®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	5.3	0.2	10.3	10.8
<b>Levemir®Penfill® NovoPen® 4</b>	6.9	0.6	0.1	3.3	0.3	5.3	0.2	16.0	16.6
<b>Mixtard®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	5.3	0.2	10.3	10.8
<b>NovoMix®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	5.3	0.2	10.2	10.7
<b>NovoRapid®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	5.3	0.2	10.2	10.7
<b>Ryzodeg®Penfill® NovoPen® 4</b>	1.8	0.6	0.1	3.3	0.3	5.3	0.2	11.0	11.5
<b>Tresiba®Penfill® NovoPen® 4</b>	2.1	0.6	0.1	3.3	0.3	5.3	0.2	11.3	11.8

Table 8. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **US** market with NovoPen® 4 and NovoFine® Plus

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 4 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	2.8	0.2	7.8	8.3

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 4 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Fiasp®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	2.8	0.2	7.7	8.3
<b>Insulatard®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	2.8	0.2	7.8	8.3
<b>Levemir®Penfill® NovoPen® 4</b>	6.9	0.6	0.1	3.3	0.3	2.8	0.2	13.6	14.1
<b>Mixtard®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	2.8	0.2	7.8	8.3
<b>NovoMix®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	2.8	0.2	7.7	8.3
<b>NovoRapid®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	2.8	0.2	7.7	8.3
<b>Ryzodeg®Penfill® NovoPen® 4</b>	1.8	0.6	0.1	3.3	0.3	2.8	0.2	8.5	9.0
<b>Tresiba®Penfill® NovoPen® 4</b>	2.1	0.6	0.1	3.3	0.3	2.8	0.2	8.8	9.3

Table 9. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **US** market with NovoPen® 4 and NovoFine® Plus (co-pack).

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 4 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus (co-pack) [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	6.8	3.0	11.8	15.1
<b>Fiasp®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	6.8	3.0	11.8	15.1
<b>Insulatard®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	6.8	3.0	11.8	15.1

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 4 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus (co-pack) [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Levemir®Penfill® NovoPen® 4</b>	6.9	0.6	0.1	3.3	0.3	6.8	3.0	17.6	20.9
<b>Mixtard®Penfil® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	6.8	3.0	11.8	15.1
<b>NovoMix®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	6.8	3.0	11.8	15.1
<b>NovoRapid®Penfill® NovoPen® 4</b>	1.1	0.6	0.1	3.3	0.3	6.8	3.0	11.8	15.1
<b>Ryzodeg®Penfill® NovoPen® 4</b>	1.8	0.6	0.1	3.3	0.3	6.8	3.0	12.5	15.8
<b>Tresiba®Penfill® NovoPen® 4</b>	2.1	0.6	0.1	3.3	0.3	6.8	3.0	12.8	16.1

### 3.4.3 Japanese market

Table 10. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **Japanese** market (NovoFine plus 70pcs).

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 4 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 4</b>	1.1	0.3	0.1	4.1	0.4	3.1	0.3	8.7	9.4
<b>Fiasp®Penfill® NovoPen® 4</b>	1.1	0.3	0.1	4.1	0.4	3.1	0.3	8.6	9.4
<b>Insulatard®Penfill® NovoPen® 4</b>	1.1	0.3	0.1	4.1	0.4	3.1	0.3	8.7	9.4
<b>Levemir®Penfill® NovoPen® 4</b>	6.9	0.3	0.1	4.1	0.4	3.1	0.3	14.4	15.2
<b>Mixtard®Penfil® NovoPen® 4</b>	1.1	0.3	0.1	4.1	0.4	3.1	0.3	8.7	9.4

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 4 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>NovoMix®Penfill® NovoPen® 4</b>	1.1	0.3	0.1	4.1	0.4	3.1	0.3	8.6	9.4
<b>NovoRapid®Penfill® NovoPen® 4</b>	1.1	0.3	0.1	4.1	0.4	3.1	0.3	8.6	9.4
<b>Ryzodeg®Penfill® NovoPen® 4</b>	1.8	0.3	0.1	4.1	0.4	3.1	0.3	9.3	10.1
<b>Tresiba®Penfill® NovoPen® 4</b>	2.1	0.3	0.1	4.1	0.4	3.1	0.3	9.6	10.4

### 3.4.4 Comparison to other measurements

To put this into perspective for a non-expert, the carbon footprint of the yearly treatment (including API, delivery system, needle (NovoFine®Plus) and packaging) has been recalculated into a distance driven by an average new car at the European market in 2023<sup>6</sup>.

One year of treatment with [drug substance brand name] NovoPen® 4 corresponds to driving 79-143 km in an average new car in Europe. For a more detailed comparison, select a specific treatment in Table 11.

Table 11. The distance (km) travelled in an average new car in Europe that would equal the carbon footprint of one year's treatment of a patient with the specified treatment.

Brand name	EU	US	JP
	<i>Km travelled</i>	<i>Km travelled</i>	<i>Km travelled</i>
<b>Actrapid®Penfill® NovoPen® 4</b>	80	78	89
<b>Fiasp®Penfill® NovoPen® 4</b>	79	78	88
<b>Insulatard®Penfill® NovoPen® 4</b>	80	78	89
<b>Levemir®Penfill® NovoPen® 4</b>	134	132	143
<b>Mixtard®Penfill® NovoPen® 4</b>	80	78	89
<b>NovoMix®Penfill® NovoPen® 4</b>	79	78	88
<b>NovoRapid®Penfill® NovoPen® 4</b>	79	78	88

<sup>6</sup> European Environment Agency (2023) . Average carbon dioxide emissions per km from new passenger cars (106.4 g CO<sub>2</sub> eq/km), [CO<sub>2</sub> emissions performance of new passenger cars in Europe | European Environment Agency's home page](#)

Brand name	EU	US	JP
	<i>Km travelled</i>	<i>Km travelled</i>	<i>Km travelled</i>
<b>Ryzodeg®Penfill® NovoPen® 4</b>	86	85	95
<b>Tresiba®Penfill® NovoPen® 4</b>	89	88	98

### 3.5 Plastic footprint NovoPen® 4

The plastic footprint is defined by Novo Nordisk as the amount of plastic<sup>7</sup> used by a patient or an organisation during a specific treatment. The footprint includes any plastic placed on the market by Novo Nordisk, regardless of its origin (virgin, recycled, fossil or non-fossil). The footprint is calculated both with and without secondary and tertiary packaging.

This section presents the plastic footprint for specific treatments (assumptions described in Section 2) with NovoPen® 4 in combinations with a range on drug substances (delivered in Penfill®) and needles in the three representative markets, Europe, US and Japan. The contribution to the plastic footprints from the delivery system, cartridge, needle and packaging are shown as well as the total plastic footprint per patient per year.

Table 12 Plastic footprint for the delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for yearly treatment with *NovoPen® 4* combined with NovoFine® with and without packaging. The softcase for the NovoPen is included in "device".

Brand name	NovoPen® 4 [g plastic/year]		Penfill® [g plastic/year]		NovoFine® [g plastic/year]		One year treatment [kg plastic/year]	
	Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
	All	EU/US	All	EU/US	All	EU/US	All	EU/US
<b>Actrapid®Penfill® NovoPen® 4</b>	17	0.3	15	50	394	2	0.43	0.48
<b>Fiasp®Penfill® NovoPen® 4</b>	17	0.3	15	50	394	2	0.43	0.48
<b>Insulatard®Penfill® NovoPen® 4</b>	17	0.3	15	50	394	2	0.43	0.48
<b>Levemir®Penfill® NovoPen® 4</b>	17	0.3	15	50	394	2	0.43	0.48
<b>Mixtard®Penfil® NovoPen® 4</b>	17	0.3	15	50	394	2	0.43	0.48
<b>NovoMix®Penfill® NovoPen® 4</b>	17	0.3	15	50	394	2	0.43	0.48
<b>NovoRapid®Penfill® NovoPen® 4</b>	17	0.3	15	50	394	2	0.43	0.48
<b>Ryzodeg®Penfill® NovoPen® 4</b>	17	0.3	15	50	394	2	0.43	0.48

<sup>7</sup> Rubber not included



Brand name	NovoPen® 4 [g plastic/year]		Penfill® [g plastic/year]		NovoFine® [g plastic/year]		One year treatment [kg plastic/year]	
	Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
	All	EU/US	All	EU/US	All	EU/US	All	EU/US
<b>Tresiba®Penfill® NovoPen® 4</b>	17	0.3	15	50	394	2	0.43	0.48

Table 13. Plastic footprint for the delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for yearly treatment with *NovoPen® 4* combined with NovoFine® Plus with and without packaging.

Brand name	NovoPen® 4 [g plastic/year]			Penfill® [g plastic/year]			NovoFine® plus [g plastic/year]			One year treatment [kg plastic/year]		
	Delivery system	Packaging		Cartridge	Packaging		Needle	Packaging		Excl. packaging	Incl. packaging	
	All	EU/US	JP	All	EU/US	JP	All	EU/US	JP	All	EU/US	JP
<b>Actrapid®Penfill® NovoPen® 4</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Fiasp®Penfill® NovoPen® 4</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Insulatard®Penfill® NovoPen® 4</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Levemir®Penfill® NovoPen® 4</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Mixtard®Penfil® NovoPen® 4</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>NovoMix®Penfill® NovoPen® 4</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>NovoRapid®Penfill® NovoPen® 4</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Ryzodeg®Penfill® NovoPen® 4</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Tresiba®Penfill® NovoPen® 4</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56

Table 14. Plastic footprint for the delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for yearly treatment with *NovoPen® 4* combined with *NovoFine® Plus* (co-pack) with and without packaging.

Brand name	NovoPen® 4 [g plastic/year]		Penfill® [g plastic/year]		NovoFine® Plus (co-pack) [g plastic/year]		One year treatment [kg plastic/year]	
	Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
	All	EU/US	All	EU/US	All	EU/US	All	EU/US
<b>Actrapid®Penfill® NovoPen® 4</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Fiasp®Penfill® NovoPen® 4</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Insulatard®Penfill® NovoPen® 4</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Levemir®Penfill® NovoPen® 4</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Mixtard®Penfill® NovoPen® 4</b>	17	0.3	15	50	402	20	0.43	0.50
<b>NovoMix®Penfill® NovoPen® 4</b>	17	0.3	15	50	402	20	0.43	0.50
<b>NovoRapid®Penfill® NovoPen® 4</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Ryzodeg®Penfill® NovoPen® 4</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Tresiba®Penfill® NovoPen® 4</b>	17	0.3	15	50	402	20	0.43	0.50

## 4. NovoPen® 5

### 4.6 Carbon footprint NovoPen® 5

This section presents the carbon footprints for specific treatments (assumptions described in Section 2) with NovoPen® 5 in combinations with a range on drug substances (delivered in Penfill®) and needles in the three representative markets, Europe, US and Japan. The contribution to the carbon footprints from drug substance, delivery system, cartridge and needles are shown as well as the total carbon footprint per patient per year.

To put the results into perspective, the resulting carbon footprints has been recalculated into the distance driven by an average car (see Section 4.6.4).

#### 4.6.1 European market

Table 15. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **European** market with NovoPen® 5 and NovoFine®

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 5 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>Fiasp®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.0
<b>Insulatard®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>Levemir®Penfill® NovoPen® 5</b>	6.9	0.5	0.1	4.5	0.2	2.6	0.2	14.4	14.9
<b>Mixtard®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>NovoMix®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.0
<b>NovoRapid®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.0
<b>Ryzodeg®Penfill® NovoPen® 5</b>	1.8	0.5	0.1	4.5	0.2	2.6	0.2	9.3	9.8
<b>Tresiba®Penfill® NovoPen® 5</b>	2.1	0.5	0.1	4.5	0.2	2.6	0.2	9.6	10.1

Table 16. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **European** market with NovoPen® 5 and NovoFine® Plus.

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 5 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>Fiasp®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.0	8.5
<b>Insulatard®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>Levemir®Penfill® NovoPen® 5</b>	6.9	0.5	0.1	4.5	0.2	2.0	0.2	13.9	14.3
<b>Mixtard®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>NovoMix®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.0	8.5
<b>NovoRapid®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.0	8.5
<b>Ryzodeg®Penfill® NovoPen® 5</b>	1.8	0.5	0.1	4.5	0.2	2.0	0.2	8.8	9.3
<b>Tresiba®Penfill® NovoPen® 5</b>	2.1	0.5	0.1	4.5	0.2	2.0	0.2	9.1	9.6

Table 17. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **European** market with NovoPen® 5 and NovoFine® Plus (co-pack).

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 5 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus (co-pack) [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.2	11.5
<b>Fiasp®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.1	11.4
<b>Insulatard®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.2	11.5
<b>Levemir®Penfill® NovoPen® 5</b>	6.9	0.5	0.1	4.5	0.2	2.1	3.0	13.9	17.3
<b>Mixtard®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.2	11.5
<b>NovoMix®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.1	11.4
<b>NovoRapid®Penfill® NovoPen® 5</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.1	11.4
<b>Ryzodeg®Penfill® NovoPen® 5</b>	1.8	0.5	0.1	4.5	0.2	2.1	3.0	8.8	12.2
<b>Tresiba®Penfill® NovoPen® 5</b>	2.1	0.5	0.1	4.5	0.2	2.1	3.0	9.2	12.5

## 4.6.2 US market

Table 18. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **US** market with NovoPen® 5 and NovoFine®.

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 5 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.4	10.9
<b>Fiasp®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.3	10.9
<b>Insulatard®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.4	10.9
<b>Levemir®Penfill® NovoPen® 5</b>	6.9	0.7	0.1	3.3	0.3	5.3	0.2	16.1	16.7
<b>Mixtard®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.4	10.9
<b>NovoMix®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.3	10.9
<b>NovoRapid®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.3	10.9
<b>Ryzodeg®Penfill® NovoPen® 5</b>	1.8	0.7	0.1	3.3	0.3	5.3	0.2	11.1	11.6
<b>Tresiba®Penfill® NovoPen® 5</b>	2.1	0.7	0.1	3.3	0.3	5.3	0.2	11.4	11.9

Table 19. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **US** market with NovoPen® 5 and NovoFine® Plus

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 5 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.4

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 5 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Fiasp®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.8	8.4
<b>Insulatard®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.4
<b>Levemir®Penfill® NovoPen® 5</b>	6.9	0.7	0.1	3.3	0.3	2.8	0.2	13.7	14.2
<b>Mixtard®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.4
<b>NovoMix®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.8	8.4
<b>NovoRapid®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.8	8.4
<b>Ryzodeg®Penfill® NovoPen® 5</b>	1.8	0.7	0.1	3.3	0.3	2.8	0.2	8.6	9.1
<b>Tresiba®Penfill® NovoPen® 5</b>	2.1	0.7	0.1	3.3	0.3	2.8	0.2	8.9	9.4

Table 20. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **US** market with NovoPen® 5 and NovoFine® Plus (co-pack).

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 5 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus (co-pack) [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>Fiasp®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>Insulatard®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 5 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus (co-pack) [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Levemir®Penfill® NovoPen® 5</b>	6.9	0.7	0.1	3.3	0.3	6.8	3.0	17.7	21.0
<b>Mixtard®Penfil® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>NovoMix®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>NovoRapid®Penfill® NovoPen® 5</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>Ryzodeg®Penfill® NovoPen® 5</b>	1.8	0.7	0.1	3.3	0.3	6.8	3.0	12.6	15.9
<b>Tresiba®Penfill® NovoPen® 5</b>	2.1	0.7	0.1	3.3	0.3	6.8	3.0	12.9	16.2

#### 4.6.3 Japanese market

Table 21. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **Japanese** market (NovoFine plus 70pcs).

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 5 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 5</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.8	9.5
<b>Fiasp®Penfill® NovoPen® 5</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.7	9.5
<b>Insulatard®Penfill® NovoPen® 5</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.8	9.5
<b>Levemir®Penfill® NovoPen® 5</b>	6.9	0.4	0.1	4.1	0.4	3.1	0.3	14.5	15.3
<b>Mixtard®Penfil® NovoPen® 5</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.8	9.5



Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 5 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>NovoMix®Penfill® NovoPen® 5</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.7	9.5
<b>NovoRapid®Penfill® NovoPen® 5</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.7	9.5
<b>Ryzodeg®Penfill® NovoPen® 5</b>	1.8	0.4	0.1	4.1	0.4	3.1	0.3	9.4	10.2
<b>Tresiba®Penfill® NovoPen® 5</b>	2.1	0.4	0.1	4.1	0.4	3.1	0.3	9.7	10.5

#### 4.6.4 Comparison to other measurements

To put this into perspective for a non-expert, the carbon footprint of the yearly treatment (including API, delivery system, needle (NovoFine®Plus) and packaging) has been recalculated into a distance driven by an average new car at the European market in 2023<sup>8</sup>.

One year of treatment with [drug substance brand name] NovoPen® 5 corresponds to driving 79-144 km in an average new car in Europe. For a more detailed comparison, select a specific treatment in Table 22.

Table 22 The distance (km) travelled in an average new car in Europe that would equal the carbon footprint of one year's treatment of a patient with the specified treatment.

Brand name	EU	US	JP
	<i>Km travelled</i>	<i>Km travelled</i>	<i>Km travelled</i>
<b>Actrapid®Penfill® NovoPen® 5</b>	81	79	89
<b>Fiasp®Penfill® NovoPen® 5</b>	80	79	89
<b>Insulatard®Penfill® NovoPen® 5</b>	81	79	89
<b>Levemir®Penfill® NovoPen® 5</b>	135	133	144
<b>Mixtard®Penfill® NovoPen® 5</b>	81	79	89
<b>NovoMix®Penfill® NovoPen® 5</b>	80	79	89
<b>NovoRapid®Penfill® NovoPen® 5</b>	80	79	89

<sup>8</sup> European Environment Agency (2023) . Average carbon dioxide emissions per km from new passenger cars (106.4 g CO<sub>2</sub> eq/km), [CO<sub>2</sub> emissions performance of new passenger cars in Europe | European Environment Agency's home page](#)

Brand name	EU	US	JP
	<i>Km travelled</i>	<i>Km travelled</i>	<i>Km travelled</i>
<b>Ryzodeg®Penfill® NovoPen® 5</b>	87	86	96
<b>Tresiba®Penfill® NovoPen® 5</b>	90	88	99

## 4.7 Plastic footprint NovoPen® 5

The plastic footprint is defined by Novo Nordisk as the amount of plastic<sup>9</sup> used by a patient or an organisation during a specific treatment. The footprint includes any plastic placed on the market by Novo Nordisk, regardless of its origin (virgin, recycled, fossil or non-fossil). The footprint is calculated both with and without secondary and tertiary packaging.

This section presents the plastic footprint for specific treatments (assumptions described in Section 2) with NovoPen® 5 in combinations with a range on drug substances (delivered in Penfill®) and needles in the three representative markets, Europe, US and Japan. The contribution to the plastic footprints from the delivery system, cartridge, needle and packaging are shown as well as the total plastic footprint per patient per year.

Table 23 Plastic footprint for the delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for yearly treatment with NovoPen® 5 combined with NovoFine® with and without packaging. The softcase for the NovoPen is included in "device".

Brand name	NovoPen® 5 [g plastic/year]		Penfill® [g plastic/year]		NovoFine® [g plastic/year]		One year treatment [kg plastic/year]	
	Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
	All	EU/US	All	EU/US	All	EU/US	All	EU/US
<b>Actrapid®Penfill® NovoPen® 5</b>	16	0.3	15	50	394	2	0.43	0.48
<b>Fiasp®Penfill® NovoPen® 5</b>	16	0.3	15	50	394	2	0.43	0.48
<b>Insulatard®Penfill® NovoPen® 5</b>	16	0.3	15	50	394	2	0.43	0.48
<b>Levemir®Penfill® NovoPen® 5</b>	16	0.3	15	50	394	2	0.43	0.48
<b>Mixtard®Penfil® NovoPen® 5</b>	16	0.3	15	50	394	2	0.43	0.48
<b>NovoMix®Penfill® NovoPen® 5</b>	16	0.3	15	50	394	2	0.43	0.48
<b>NovoRapid®Penfill® NovoPen® 5</b>	16	0.3	15	50	394	2	0.43	0.48
<b>Ryzodeg®Penfill® NovoPen® 5</b>	16	0.3	15	50	394	2	0.43	0.48

<sup>9</sup> Rubber not included

Brand name	NovoPen® 5 [g plastic/year]		Penfill® [g plastic/year]		NovoFine® [g plastic/year]		One year treatment [kg plastic/year]	
	Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
	All	EU/US	All	EU/US	All	EU/US	All	EU/US
<b>Tresiba®Penfill® NovoPen® 5</b>	16	0.3	15	50	394	2	0.43	0.48

Table 24. Plastic footprint for the delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for yearly treatment with *NovoPen® 5* combined with NovoFine® Plus with and without packaging.

Brand name	NovoPen® 5 [g plastic/year]			Penfill® [g plastic/year]			NovoFine® plus [g plastic/year]			One year treatment [kg plastic/year]		
	Delivery system	Packaging		Cartridge	Packaging		Needle	Packaging		Excl. packaging	Incl. packaging	
	All	EU/US	JP	All	EU/US	JP	All	EU/US	JP	All	EU/US	JP
<b>Actrapid®Penfill® NovoPen® 5</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Fiasp®Penfill® NovoPen® 5</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Insulatard®Penfill® NovoPen® 5</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Levemir®Penfill® NovoPen® 5</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Mixtard®Penfil® NovoPen® 5</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>NovoMix®Penfill® NovoPen® 5</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>NovoRapid®Penfill® NovoPen® 5</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Ryzodeg®Penfill® NovoPen® 5</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Tresiba®Penfill® NovoPen® 5</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56

Table 25. Plastic footprint for the delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for yearly treatment with *NovoPen*® 5 combined with *NovoFine*® Plus (co-pack) with and without packaging.

Brand name	NovoPen® 5 [g plastic/year]		Penfill® [g plastic/year]		NovoFine® Plus (co-pack) [g plastic/year]		One year treatment [kg plastic/year]	
	Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
	All	EU/US	All	EU/US	All	EU/US	All	EU/US
<b>Actrapid®Penfill® NovoPen® 5</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Fiasp®Penfill® NovoPen® 5</b>	16	0.3	15	50	402	20	0.43	0.50
<b>Insulatard®Penfill® NovoPen® 5</b>	16	0.3	15	50	402	20	0.43	0.50
<b>Levemir®Penfill® NovoPen® 5</b>	16	0.3	15	50	402	20	0.43	0.50
<b>Mixtard®Penfill® NovoPen® 5</b>	16	0.3	15	50	402	20	0.43	0.50
<b>NovoMix®Penfill® NovoPen® 5</b>	16	0.3	15	50	402	20	0.43	0.50
<b>NovoRapid®Penfill® NovoPen® 5</b>	16	0.3	15	50	402	20	0.43	0.50
<b>Ryzodeg®Penfill® NovoPen® 5</b>	16	0.3	15	50	402	20	0.43	0.50
<b>Tresiba®Penfill® NovoPen® 5</b>	16	0.3	15	50	402	20	0.43	0.50

## 5. NovoPen® 6

### 5.8 Carbon footprint NovoPen® 6

This section presents the carbon footprints for specific treatments (assumptions described in Section 2) with NovoPen® 6 in combinations with a range on drug substances (delivered in Penfill®) and needles in the three representative markets, Europe, US and Japan. The contribution to the carbon footprints from drug substance, delivery system, cartridge and needles are shown as well as the total carbon footprint per patient per year.

To put the results into perspective, the resulting carbon footprints has been recalculated into the distance driven by an average car (see Section 5.8.4).

#### 5.8.1 European market

Table 26. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **European** market with NovoPen® 6 and NovoFine®

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 6 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>Fiasp®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>Insulatard®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>Levemir®Penfill® NovoPen® 6</b>	6.9	0.5	0.1	4.5	0.2	2.6	0.2	14.4	14.9
<b>Mixtard®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>NovoMix®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>NovoRapid®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>Ryzodeg®Penfill® NovoPen® 6</b>	1.8	0.5	0.1	4.5	0.2	2.6	0.2	9.3	9.8
<b>Tresiba®Penfill® NovoPen® 6</b>	2.1	0.5	0.1	4.5	0.2	2.6	0.2	9.6	10.1

Table 27. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **European** market with NovoPen® 6 and NovoFine® Plus.

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 6 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>Fiasp®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>Insulatard®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>Levemir®Penfill® NovoPen® 6</b>	6.9	0.5	0.1	4.5	0.2	2.0	0.2	13.9	14.4
<b>Mixtard®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>NovoMix®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>NovoRapid®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>Ryzodeg®Penfill® NovoPen® 6</b>	1.8	0.5	0.1	4.5	0.2	2.0	0.2	8.8	9.3
<b>Tresiba®Penfill® NovoPen® 6</b>	2.1	0.5	0.1	4.5	0.2	2.0	0.2	9.1	9.6

Table 28. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **European** market with NovoPen® 6 and NovoFine® Plus (co-pack).

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 6 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus (co-pack) [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.2	11.5
<b>Fiasp®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.1	11.5
<b>Insulatard®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.2	11.5
<b>Levemir®Penfill® NovoPen® 6</b>	6.9	0.5	0.1	4.5	0.2	2.1	3.0	14.0	17.3
<b>Mixtard®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.2	11.5
<b>NovoMix®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.1	11.5
<b>NovoRapid®Penfill® NovoPen® 6</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.1	11.5
<b>Ryzodeg®Penfill® NovoPen® 6</b>	1.8	0.5	0.1	4.5	0.2	2.1	3.0	8.9	12.2
<b>Tresiba®Penfill® NovoPen® 6</b>	2.1	0.5	0.1	4.5	0.2	2.1	3.0	9.2	12.5



## 5.8.2 US market

Table 29. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **US** market with NovoPen® 6 and NovoFine®.

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 6 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.4	10.9
<b>Fiasp®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.3	10.9
<b>Insulatard®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.4	10.9
<b>Levemir®Penfill® NovoPen® 6</b>	6.9	0.7	0.1	3.3	0.3	5.3	0.2	16.2	16.7
<b>Mixtard®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.4	10.9
<b>NovoMix®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.3	10.9
<b>NovoRapid®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.3	10.9
<b>Ryzodeg®Penfill® NovoPen® 6</b>	1.8	0.7	0.1	3.3	0.3	5.3	0.2	11.1	11.6
<b>Tresiba®Penfill® NovoPen® 6</b>	2.1	0.7	0.1	3.3	0.3	5.3	0.2	11.4	11.9

Table 30. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **US** market with NovoPen® 6 and NovoFine® Plus

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 6 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.5

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 6 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Fiasp®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.4
<b>Insulatard®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.5
<b>Levemir®Penfill® NovoPen® 6</b>	6.9	0.7	0.1	3.3	0.3	2.8	0.2	13.7	14.2
<b>Mixtard®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.5
<b>NovoMix®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.4
<b>NovoRapid®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.4
<b>Ryzodeg®Penfill® NovoPen® 6</b>	1.8	0.7	0.1	3.3	0.3	2.8	0.2	8.6	9.1
<b>Tresiba®Penfill® NovoPen® 6</b>	2.1	0.7	0.1	3.3	0.3	2.8	0.2	8.9	9.4

Table 31. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **US** market with NovoPen® 6 and NovoFine® Plus (co-pack).

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 6 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus (co-pack) [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>Fiasp®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>Insulatard®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 6 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus (co-pack) [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Levemir®Penfill® NovoPen® 6</b>	6.9	0.7	0.1	3.3	0.3	6.8	3.0	17.7	21.0
<b>Mixtard®Penfil® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>NovoMix®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>NovoRapid®Penfill® NovoPen® 6</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>Ryzodeg®Penfill® NovoPen® 6</b>	1.8	0.7	0.1	3.3	0.3	6.8	3.0	12.6	15.9
<b>Tresiba®Penfill® NovoPen® 6</b>	2.1	0.7	0.1	3.3	0.3	6.8	3.0	12.9	16.2

### 5.8.3 Japanese market

Table 32. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **Japanese** market (NovoFine plus 70pcs).

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 6 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen® 6</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.8	9.5
<b>Fiasp®Penfill® NovoPen® 6</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.7	9.5
<b>Insulatard®Penfill® NovoPen® 6</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.8	9.5
<b>Levemir®Penfill® NovoPen® 6</b>	6.9	0.4	0.1	4.1	0.4	3.1	0.3	14.5	15.3
<b>Mixtard®Penfil® NovoPen® 6</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.8	9.5

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen® 6 [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>NovoMix®Penfill® NovoPen® 6</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.7	9.5
<b>NovoRapid®Penfill® NovoPen® 6</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.7	9.5
<b>Ryzodeg®Penfill® NovoPen® 6</b>	1.8	0.4	0.1	4.1	0.4	3.1	0.3	9.5	10.2
<b>Tresiba®Penfill® NovoPen® 6</b>	2.1	0.4	0.1	4.1	0.4	3.1	0.3	9.8	10.5

#### 5.8.4 Comparison to other measurements

To put this into perspective for a non-expert, the carbon footprint of the yearly treatment (including API, delivery system, needle (NovoFine®Plus) and packaging) has been recalculated into a distance driven by an average new car at the European market in 2023<sup>10</sup>.

One year of treatment with [drug substance brand name] NovoPen® 6 corresponds to driving 80-144 km in an average new car in Europe. For a more detailed comparison, select a specific treatment in Table 33.

Table 33. The distance (km) travelled in an average new car in Europe that would equal the carbon footprint of one year's treatment of a patient with the specified treatment.

Brand name	EU	US	JP
	<i>Km travelled</i>	<i>Km travelled</i>	<i>Km travelled</i>
<b>Actrapid®Penfill® NovoPen® 6</b>	81	80	90
<b>Fiasp®Penfill® NovoPen® 6</b>	80	79	89
<b>Insulatard®Penfill® NovoPen® 6</b>	81	80	90
<b>Levemir®Penfill® NovoPen® 6</b>	135	134	144
<b>Mixtard®Penfill® NovoPen® 6</b>	81	80	90
<b>NovoMix®Penfill® NovoPen® 6</b>	80	79	89
<b>NovoRapid®Penfill® NovoPen® 6</b>	80	79	89

<sup>10</sup> European Environment Agency (2023) . Average carbon dioxide emissions per km from new passenger cars (106.4 g CO<sub>2</sub> eq/km), [CO<sub>2</sub> emissions performance of new passenger cars in Europe | European Environment Agency's home page](#)

Brand name	EU	US	JP
	<i>Km travelled</i>	<i>Km travelled</i>	<i>Km travelled</i>
<b>Ryzodeg® Penfill® NovoPen® 6</b>	87	86	96
<b>Tresiba® Penfill® NovoPen® 6</b>	90	89	99

## 5.9 Plastic footprint NovoPen® 6

The plastic footprint is defined by Novo Nordisk as the amount of plastic<sup>11</sup> used by a patient or an organisation during a specific treatment. The footprint includes any plastic placed on the market by Novo Nordisk, regardless of its origin (virgin, recycled, fossil or non-fossil). The footprint is calculated both with and without secondary and tertiary packaging.

This section presents the plastic footprint for specific treatments (assumptions described in Section 2) with NovoPen® 6 in combinations with a range on drug substances (delivered in Penfill®) and needles in the three representative markets, Europe, US and Japan. The contribution to the plastic footprints from the delivery system, cartridge, needle and packaging are shown as well as the total plastic footprint per patient per year.

Table 34. Plastic footprint for the delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for yearly treatment with NovoPen® 6 combined with NovoFine® with and without packaging. The softcase for the NovoPen is included in "device".

Brand name	NovoPen® 6 [g plastic/year]		Penfill® [g plastic/year]		NovoFine® [g plastic/year]		One year treatment [kg plastic/year]	
	Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
	All	EU/US	All	EU/US	All	EU/US	All	EU/US
<b>Actrapid®Penfill® NovoPen® 6</b>	16	0.3	15	50	394	2	0.43	0.48
<b>Fiasp®Penfill® NovoPen® 6</b>	16	0.3	15	50	394	2	0.43	0.48
<b>Insulatard®Penfill® NovoPen® 6</b>	16	0.3	15	50	394	2	0.43	0.48
<b>Levemir®Penfill® NovoPen® 6</b>	16	0.3	15	50	394	2	0.43	0.48
<b>Mixtard®Penfil® NovoPen® 6</b>	16	0.3	15	50	394	2	0.43	0.48
<b>NovoMix®Penfill® NovoPen® 6</b>	16	0.3	15	50	394	2	0.43	0.48
<b>NovoRapid®Penfill® NovoPen® 6</b>	16	0.3	15	50	394	2	0.43	0.48
<b>Ryzodeg®Penfill® NovoPen® 6</b>	16	0.3	15	50	394	2	0.43	0.48

<sup>11</sup> Rubber not included

Brand name	NovoPen® 6 [g plastic/year]		Penfill® [g plastic/year]		NovoFine® [g plastic/year]		One year treatment [kg plastic/year]	
	Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
	All	EU/US	All	EU/US	All	EU/US	All	EU/US
<b>Tresiba®Penfill® NovoPen® 6</b>	16	0.3	15	50	394	2	0.43	0.48

Table 35. Plastic footprint for the delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for yearly treatment with *NovoPen® 6* combined with NovoFine® Plus with and without packaging.

Brand name	NovoPen® 6 [g plastic/year]			Penfill® [g plastic/year]			NovoFine® plus [g plastic/year]			One year treatment [kg plastic/year]		
	Delivery system	Packaging		Cartridge	Packaging		Needle	Packaging		Excl. packaging	Incl. packaging	
	All	EU/US	JP	All	EU/US	JP	All	EU/US	JP	All	EU/US	JP
<b>Actrapid®Penfill® NovoPen® 6</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Fiasp®Penfill® NovoPen® 6</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Insulatard®Penfill® NovoPen® 6</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Levemir®Penfill® NovoPen® 6</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Mixtard®Penfill® NovoPen® 6</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>NovoMix®Penfill® NovoPen® 6</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>NovoRapid®Penfill® NovoPen® 6</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Ryzodeg®Penfill® NovoPen® 6</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Tresiba®Penfill® NovoPen® 6</b>	16	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56

Table 36. Plastic footprint for the delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for yearly treatment with *NovoPen® 6* combined with *NovoFine® Plus* (co-pack) with and without packaging.

Brand name	NovoPen® 6 [g plastic/year]		Penfill® [g plastic/year]		NovoFine® Plus (co-pack) [g plastic/year]		One year treatment [kg plastic/year]	
	Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
	All	EU/US	All	EU/US	All	EU/US	All	EU/US
<b>Actrapid®Penfill® NovoPen® 6</b>	16	0.3	15	50	402	20	0.43	0.50
<b>Fiasp®Penfill® NovoPen® 6</b>	16	0.3	15	50	402	20	0.43	0.50
<b>Insulatard®Penfill® NovoPen® 6</b>	16	0.3	15	50	402	20	0.43	0.50
<b>Levemir®Penfill® NovoPen® 6</b>	16	0.3	15	50	402	20	0.43	0.50
<b>Mixtard®Penfill® NovoPen® 6</b>	16	0.3	15	50	402	20	0.43	0.50
<b>NovoMix®Penfill® NovoPen® 6</b>	16	0.3	15	50	402	20	0.43	0.50
<b>NovoRapid®Penfill® NovoPen® 6</b>	16	0.3	15	50	402	20	0.43	0.50
<b>Ryzodeg®Penfill® NovoPen® 6</b>	16	0.3	15	50	402	20	0.43	0.50
<b>Tresiba®Penfill® NovoPen® 6</b>	16	0.3	15	50	402	20	0.43	0.50



## 6. NovoPen Echo®

### 6.10 Carbon footprint NovoPen Echo®

This section presents the carbon footprints for specific treatments (assumptions described in Section 2) with NovoPen Echo® in combinations with a range on drug substances (delivered in Penfill®) and needles in the three representative markets, Europe, US and Japan. The contribution to the carbon footprints from drug substance, delivery system, cartridge and needles are shown as well as the total carbon footprint per patient per year.

To put the results into perspective, the resulting carbon footprints has been recalculated into the distance driven by an average car (see Section 6.10.4).

#### 6.10.1 European market

Table 37. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **European** market with NovoPen Echo® and NovoFine®

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>Fiasp®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.0
<b>Insulatard®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>Levemir®Penfill® NovoPen Echo®</b>	6.9	0.5	0.1	4.5	0.2	2.6	0.2	14.4	14.9
<b>Mixtard®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>NovoMix®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.0
<b>NovoRapid®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.0
<b>Ryzodeg®Penfill® NovoPen Echo®</b>	1.8	0.5	0.1	4.5	0.2	2.6	0.2	9.3	9.8
<b>Tresiba®Penfill® NovoPen Echo®</b>	2.1	0.5	0.1	4.5	0.2	2.6	0.2	9.6	10.1

Table 38. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **European** market with NovoPen Echo® and NovoFine® Plus.

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>Fiasp®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.0	8.5
<b>Insulatard®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>Levemir®Penfill® NovoPen Echo®</b>	6.9	0.5	0.1	4.5	0.2	2.0	0.2	13.9	14.3
<b>Mixtard®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>NovoMix®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.0	8.5
<b>NovoRapid®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.0	8.5
<b>Ryzodeg®Penfill® NovoPen Echo®</b>	1.8	0.5	0.1	4.5	0.2	2.0	0.2	8.8	9.3
<b>Tresiba®Penfill® NovoPen Echo®</b>	2.1	0.5	0.1	4.5	0.2	2.0	0.2	9.1	9.6

Table 39. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **European** market with NovoPen Echo® and NovoFine® Plus (co-pack).

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus (co-pack) [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.2	11.5
<b>Fiasp®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.1	11.4
<b>Insulatard®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.2	11.5
<b>Levemir®Penfill® NovoPen Echo®</b>	6.9	0.5	0.1	4.5	0.2	2.1	3.0	13.9	17.3
<b>Mixtard®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.2	11.5
<b>NovoMix®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.1	11.4
<b>NovoRapid®Penfill® NovoPen Echo®</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.1	11.4
<b>Ryzodeg®Penfill® NovoPen Echo®</b>	1.8	0.5	0.1	4.5	0.2	2.1	3.0	8.8	12.2
<b>Tresiba®Penfill® NovoPen Echo®</b>	2.1	0.5	0.1	4.5	0.2	2.1	3.0	9.2	12.5

## 6.10.2 US market

Table 40. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **US** market with NovoPen Echo® and NovoFine®.

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.4	10.9
<b>Fiasp®Penfill® NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.3	10.9
<b>Insulatard®Penfill® NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.4	10.9
<b>Levemir®Penfill® NovoPen Echo®</b>	6.9	0.7	0.1	3.3	0.3	5.3	0.2	16.1	16.7
<b>Mixtard®Penfill® NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.4	10.9
<b>NovoMix®Penfill® NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.3	10.9
<b>NovoRapid®Penfill® NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.3	10.9
<b>Ryzodeg®Penfill® NovoPen Echo®</b>	1.8	0.7	0.1	3.3	0.3	5.3	0.2	11.1	11.6
<b>Tresiba®Penfill® NovoPen Echo®</b>	2.1	0.7	0.1	3.3	0.3	5.3	0.2	11.4	11.9

Table 41. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **US** market with NovoPen Echo® and NovoFine® Plus

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.4

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Fiasp®Penfill®</b> <b>NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.8	8.4
<b>Insulatard®Penfill®</b> <b>NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.4
<b>Levemir®Penfill®</b> <b>NovoPen Echo®</b>	6.9	0.7	0.1	3.3	0.3	2.8	0.2	13.7	14.2
<b>Mixtard®Penfill®</b> <b>NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.4
<b>NovoMix®Penfill®</b> <b>NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.8	8.4
<b>NovoRapid®Penfill®</b> <b>NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.8	8.4
<b>Ryzodeg®Penfill®</b> <b>NovoPen Echo®</b>	1.8	0.7	0.1	3.3	0.3	2.8	0.2	8.6	9.1
<b>Tresiba®Penfill®</b> <b>NovoPen Echo®</b>	2.1	0.7	0.1	3.3	0.3	2.8	0.2	8.9	9.4

Table 42. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **US** market with NovoPen Echo® and NovoFine® Plus (co-pack).

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus (co-pack) [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill®</b> <b>NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>Fiasp®Penfill®</b> <b>NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>Insulatard®Penfill®</b> <b>NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus (co-pack) [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Levemir®Penfill® NovoPen Echo®</b>	6.9	0.7	0.1	3.3	0.3	6.8	3.0	17.7	21.0
<b>Mixtard®Penfil® NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>NovoMix®Penfill® NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>NovoRapid®Penfill® NovoPen Echo®</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>Ryzodeg®Penfill® NovoPen Echo®</b>	1.8	0.7	0.1	3.3	0.3	6.8	3.0	12.6	15.9
<b>Tresiba®Penfill® NovoPen Echo®</b>	2.1	0.7	0.1	3.3	0.3	6.8	3.0	12.9	16.2

### 6.10.3 Japanese market

Table 43. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **Japanese** market (NovoFine plus 70pcs).

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen Echo®</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.8	9.5
<b>Fiasp®Penfill® NovoPen Echo®</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.7	9.5
<b>Insulatard®Penfill® NovoPen Echo®</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.8	9.5
<b>Levemir®Penfill® NovoPen Echo®</b>	6.9	0.4	0.1	4.1	0.4	3.1	0.3	14.5	15.3
<b>Mixtard®Penfil® NovoPen Echo®</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.8	9.5

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>NovoMix®Penfill® NovoPen Echo®</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.7	9.5
<b>NovoRapid®Penfill® NovoPen Echo®</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.7	9.5
<b>Ryzodeg®Penfill® NovoPen Echo®</b>	1.8	0.4	0.1	4.1	0.4	3.1	0.3	9.4	10.2
<b>Tresiba®Penfill® NovoPen Echo®</b>	2.1	0.4	0.1	4.1	0.4	3.1	0.3	9.7	10.5

#### 6.10.4 Comparison to other measurements

To put this into perspective for a non-expert, the carbon footprint of the yearly treatment (including API, delivery system, needle (NovoFine®Plus) and packaging) has been recalculated into a distance driven by an average new car at the European market in 2023<sup>12</sup>.

One year of treatment with [drug substance brand name] NovoPen® Echo corresponds to driving 79-144 km in an average new car in Europe. For a more detailed comparison, select a specific treatment in Table 44.

Table 44. The distance (km) travelled in an average new car in Europe that would equal the carbon footprint of one year's treatment of a patient with the specified treatment.

Brand name	EU	US	JP
	<i>Km travelled</i>	<i>Km travelled</i>	<i>Km travelled</i>
<b>Actrapid®Penfill® NovoPen Echo®</b>	81	79	89
<b>Fiasp®Penfill® NovoPen Echo®</b>	80	79	89
<b>Insulatard®Penfill® NovoPen Echo®</b>	81	79	89
<b>Levemir®Penfill® NovoPen Echo®</b>	135	133	144
<b>Mixtard®Penfill® NovoPen Echo®</b>	81	79	89
<b>NovoMix®Penfill® NovoPen Echo®</b>	80	79	89
<b>NovoRapid®Penfill® NovoPen Echo®</b>	80	79	89

<sup>12</sup> European Environment Agency (2023) . Average carbon dioxide emissions per km from new passenger cars (106.4 g CO<sub>2</sub> eq/km), [CO<sub>2</sub> emissions performance of new passenger cars in Europe | European Environment Agency's home page](#)



Brand name	EU	US	JP
	<i>Km travelled</i>	<i>Km travelled</i>	<i>Km travelled</i>
Ryzodeg®Penfill® NovoPen Echo®	87	86	96
Tresiba®Penfill® NovoPen Echo®	90	88	99



## 6.11 Plastic footprint NovoPen Echo®

The plastic footprint is defined by Novo Nordisk as the amount of plastic<sup>13</sup> used by a patient or an organisation during a specific treatment. The footprint includes any plastic placed on the market by Novo Nordisk, regardless of its origin (virgin, recycled, fossil or non-fossil). The footprint is calculated both with and without secondary and tertiary packaging.

This section presents the plastic footprint for specific treatments (assumptions described in Section 2) with NovoPen Echo® in combinations with a range on drug substances (delivered in Penfill®) and needles in the three representative markets, Europe, US and Japan. The contribution to the plastic footprints from the delivery system, cartridge, needle and packaging are shown as well as the total plastic footprint per patient per year.

Table 45 Plastic footprint for the delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for yearly treatment with NovoPen® Echo combined with NovoFine® with and without packaging. The softcase for the NovoPen is included in "device".

Brand name	NovoPen Echo® [g plastic/year]		Penfill® [g plastic/year]		NovoFine® [g plastic/year]		One year treatment [kg plastic/year]	
	Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
	All	EU/US	All	EU/US	All	EU/US	All	EU/US
<b>Actrapid®Penfill® NovoPen Echo®</b>	17	0.3	15	50	394	2	0.43	0.48
<b>Fiasp®Penfill® NovoPen Echo®</b>	17	0.3	15	50	394	2	0.43	0.48
<b>Insulatard®Penfill® NovoPen Echo®</b>	17	0.3	15	50	394	2	0.43	0.48
<b>Levemir®Penfill® NovoPen Echo®</b>	17	0.3	15	50	394	2	0.43	0.48
<b>Mixtard®Penfil® NovoPen Echo®</b>	17	0.3	15	50	394	2	0.43	0.48
<b>NovoMix®Penfill® NovoPen Echo®</b>	17	0.3	15	50	394	2	0.43	0.48
<b>NovoRapid®Penfill® NovoPen Echo®</b>	17	0.3	15	50	394	2	0.43	0.48
<b>Ryzodeg®Penfill® NovoPen Echo®</b>	17	0.3	15	50	394	2	0.43	0.48

<sup>13</sup> Rubber not included

Brand name	NovoPen Echo® [g plastic/year]		Penfill® [g plastic/year]		NovoFine® [g plastic/year]		One year treatment [kg plastic/year]	
	Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
	All	EU/US	All	EU/US	All	EU/US	All	EU/US
<b>Tresiba®Penfill® NovoPen Echo®</b>	17	0.3	15	50	394	2	0.43	0.48

Table 46. Plastic footprint for the delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for yearly treatment with *NovoPen Echo®* combined with NovoFine® Plus with and without packaging.

Brand name	NovoPen Echo® [g plastic/year]			Penfill® [g plastic/year]			NovoFine® plus [g plastic/year]			One year treatment [kg plastic/year]		
	Delivery system	Packaging		Cartridge	Packaging		Needle	Packaging		Excl. packaging	Incl. packaging	
	All	EU/US	JP	All	EU/US	JP	All	EU/US	JP	All	EU/US	JP
<b>Actrapid®Penfill® NovoPen Echo®</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Fiasp®Penfill® NovoPen Echo®</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Insulatard®Penfill® NovoPen Echo®</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Levemir®Penfill® NovoPen Echo®</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Mixtard®Penfil® NovoPen Echo®</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>NovoMix®Penfill® NovoPen Echo®</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>NovoRapid®Penfill® NovoPen Echo®</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Ryzodeg®Penfill® NovoPen Echo®</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Tresiba®Penfill® NovoPen Echo®</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56

Table 47. Plastic footprint for the delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for yearly treatment with *NovoPen Echo*® combined with *NovoFine*® Plus (co-pack) with and without packaging.

Brand name	NovoPen Echo® [g plastic/year]		Penfill® [g plastic/year]		NovoFine® Plus (co-pack) [g plastic/year]		One year treatment [kg plastic/year]	
	Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
	All	EU/US	All	EU/US	All	EU/US	All	EU/US
<b>Actrapid®Penfill® NovoPen Echo®</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Fiasp®Penfill® NovoPen Echo®</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Insulatard®Penfill® NovoPen Echo®</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Levemir®Penfill® NovoPen Echo®</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Mixtard®Penfil® NovoPen Echo®</b>	17	0.3	15	50	402	20	0.43	0.50
<b>NovoMix®Penfill® NovoPen Echo®</b>	17	0.3	15	50	402	20	0.43	0.50
<b>NovoRapid®Penfill® NovoPen Echo®</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Ryzodeg®Penfill® NovoPen Echo®</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Tresiba®Penfill® NovoPen Echo®</b>	17	0.3	15	50	402	20	0.43	0.50

## 7. NovoPen Echo® Plus

### 7.12 Carbon footprint NovoPen Echo® Plus

This section presents the carbon footprints for specific treatments (assumptions described in Section 2) with NovoPen Echo® Plus in combinations with a range on drug substances (delivered in Penfill®) and needles in the three representative markets, Europe, US and Japan. The contribution to the carbon footprints from drug substance, delivery system, cartridge and needles are shown as well as the total carbon footprint per patient per year.

To put the results into perspective, the resulting carbon footprints has been recalculated into the distance driven by an average car (see Section 7.12.4).

#### 7.12.1 European market

Table 48. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **European** market with NovoPen Echo® Plus and NovoFine®

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® Plus [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>Fiasp®Penfill® NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>Insulatard®Penfill® NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>Levemir®Penfill® NovoPen Echo® Plus</b>	6.9	0.5	0.1	4.5	0.2	2.6	0.2	14.4	14.9
<b>Mixtard®Penfil® NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>NovoMix®Penfill® NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>NovoRapid®Penfill® NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.6	0.2	8.6	9.1
<b>Ryzodeg®Penfill® NovoPen Echo® Plus</b>	1.8	0.5	0.1	4.5	0.2	2.6	0.2	9.3	9.8

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® Plus [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Tresiba®Penfill® NovoPen Echo® Plus</b>	2.1	0.5	0.1	4.5	0.2	2.6	0.2	9.6	10.1

Table 49. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **European** market with NovoPen Echo® Plus and NovoFine® Plus.

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® Plus [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>Fiasp®Penfill® NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>Insulatard®Penfill® NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>Levemir®Penfill® NovoPen Echo® Plus</b>	6.9	0.5	0.1	4.5	0.2	2.0	0.2	13.9	14.4
<b>Mixtard®Penfil® NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>NovoMix®Penfill® NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>NovoRapid®Penfill® NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.0	0.2	8.1	8.6
<b>Ryzodeg®Penfill® NovoPen Echo® Plus</b>	1.8	0.5	0.1	4.5	0.2	2.0	0.2	8.8	9.3
<b>Tresiba®Penfill® NovoPen Echo® Plus</b>	2.1	0.5	0.1	4.5	0.2	2.0	0.2	9.1	9.6

Table 50. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **European** market with NovoPen Echo® Plus and NovoFine® Plus (co-pack).

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® Plus [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus (co-pack) [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.2	11.5
<b>Fiasp®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.1	11.5
<b>Insulatard®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.2	11.5
<b>Levemir®Penfill®</b> <b>NovoPen Echo® Plus</b>	6.9	0.5	0.1	4.5	0.2	2.1	3.0	14.0	17.3
<b>Mixtard®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.2	11.5
<b>NovoMix®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.1	11.5
<b>NovoRapid®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.5	0.1	4.5	0.2	2.1	3.0	8.1	11.5
<b>Ryzodeg®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.8	0.5	0.1	4.5	0.2	2.1	3.0	8.9	12.2
<b>Tresiba®Penfill®</b> <b>NovoPen Echo® Plus</b>	2.1	0.5	0.1	4.5	0.2	2.1	3.0	9.2	12.5

## 7.12.2 US market

Table 51. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **US** market with NovoPen Echo® Plus and NovoFine®.

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® Plus [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.4	10.9
<b>Fiasp®Penfill® NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.3	10.9
<b>Insulatard®Penfill® NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.4	10.9
<b>Levemir®Penfill® NovoPen Echo® Plus</b>	6.9	0.7	0.1	3.3	0.3	5.3	0.2	16.2	16.7
<b>Mixtard®Penfill® NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.4	10.9
<b>NovoMix®Penfill® NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.3	10.9
<b>NovoRapid®Penfill® NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	5.3	0.2	10.3	10.9
<b>Ryzodeg®Penfill® NovoPen Echo® Plus</b>	1.8	0.7	0.1	3.3	0.3	5.3	0.2	11.1	11.6
<b>Tresiba®Penfill® NovoPen Echo® Plus</b>	2.1	0.7	0.1	3.3	0.3	5.3	0.2	11.4	11.9

Table 52. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **US** market with NovoPen Echo® Plus and NovoFine® Plus

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® Plus [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill® NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.5

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® Plus [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Fiasp®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.4
<b>Insulatard®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.5
<b>Levemir®Penfill®</b> <b>NovoPen Echo® Plus</b>	6.9	0.7	0.1	3.3	0.3	2.8	0.2	13.7	14.2
<b>Mixtard®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.5
<b>NovoMix®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.4
<b>NovoRapid®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	2.8	0.2	7.9	8.4
<b>Ryzodeg®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.8	0.7	0.1	3.3	0.3	2.8	0.2	8.6	9.1
<b>Tresiba®Penfill®</b> <b>NovoPen Echo® Plus</b>	2.1	0.7	0.1	3.3	0.3	2.8	0.2	8.9	9.4

Table 53. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **US** market with NovoPen Echo® Plus and NovoFine® Plus (co-pack).

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® Plus [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus (co-pack) [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>Fiasp®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>Insulatard®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2



Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® Plus [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus (co-pack) [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Levemir®Penfill®</b> <b>NovoPen Echo® Plus</b>	6.9	0.7	0.1	3.3	0.3	6.8	3.0	17.7	21.0
<b>Mixtard®Penfil®</b> <b>NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>NovoMix®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>NovoRapid®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.7	0.1	3.3	0.3	6.8	3.0	11.9	15.2
<b>Ryzodeg®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.8	0.7	0.1	3.3	0.3	6.8	3.0	12.6	15.9
<b>Tresiba®Penfill®</b> <b>NovoPen Echo® Plus</b>	2.1	0.7	0.1	3.3	0.3	6.8	3.0	12.9	16.2

### 7.12.3 Japanese market

Table 54. Carbon footprint for the drug substance, delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for one year's treatment of one patient in the **Japanese** market (NovoFine plus 70pcs).

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® Plus [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>Actrapid®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.8	9.5
<b>Fiasp®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.7	9.5
<b>Insulatard®Penfill®</b> <b>NovoPen Echo® Plus</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.8	9.5
<b>Levemir®Penfill®</b> <b>NovoPen Echo® Plus</b>	6.9	0.4	0.1	4.1	0.4	3.1	0.3	14.5	15.3
<b>Mixtard®Penfil®</b> <b>NovoPen Echo® Plus</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.8	9.5

Brand name	Drug substance [kg CO <sub>2</sub> -eq./year]	NovoPen Echo® Plus [kg CO <sub>2</sub> -eq./year]		Penfill® [kg CO <sub>2</sub> -eq./year]		NovoFine® plus [kg CO <sub>2</sub> -eq./year]		One year treatment [kg CO <sub>2</sub> -eq./year]	
		Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
<b>NovoMix®Penfill® NovoPen Echo® Plus</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.7	9.5
<b>NovoRapid®Penfill® NovoPen Echo® Plus</b>	1.1	0.4	0.1	4.1	0.4	3.1	0.3	8.7	9.5
<b>Ryzodeg®Penfill® NovoPen Echo® Plus</b>	1.8	0.4	0.1	4.1	0.4	3.1	0.3	9.5	10.2
<b>Tresiba®Penfill® NovoPen Echo® Plus</b>	2.1	0.4	0.1	4.1	0.4	3.1	0.3	9.8	10.5

#### 7.12.4 Comparison to other measurements

To put this into perspective for a non-expert, the carbon footprint of the yearly treatment (including API, delivery system, needle (NovoFine®Plus) and packaging) has been recalculated into a distance driven by an average new car at the European market in 2023<sup>14</sup>.

One year of treatment with [drug substance brand name] NovoPen Echo® Plus corresponds to driving 79-144 km in an average new car in Europe. For a more detailed comparison, select a specific treatment in Table 55.

Table 55. The distance (km) travelled in an average new car in Europe that would equal the carbon footprint of one year's treatment of a patient with the specified treatment.

Brand name	EU	US	JP
	<i>Km travelled</i>	<i>Km travelled</i>	<i>Km travelled</i>
<b>Actrapid®Penfill® NovoPen Echo® Plus</b>	81	80	90
<b>Fiasp®Penfill® NovoPen Echo® Plus</b>	80	79	89
<b>Insulatard®Penfill® NovoPen Echo® Plus</b>	81	80	90
<b>Levemir®Penfill® NovoPen Echo® Plus</b>	135	134	144
<b>Mixtard®Penfill® NovoPen Echo® Plus</b>	81	80	90
<b>NovoMix®Penfill® NovoPen Echo® Plus</b>	80	79	89
<b>NovoRapid®Penfill® NovoPen Echo® Plus</b>	80	79	89

<sup>14</sup> European Environment Agency (2023) . Average carbon dioxide emissions per km from new passenger cars (106.4 g CO<sub>2</sub> eq/km), [CO<sub>2</sub> emissions performance of new passenger cars in Europe | European Environment Agency's home page](#)



Brand name	EU	US	JP
	<i>Km travelled</i>	<i>Km travelled</i>	<i>Km travelled</i>
Ryzodeg®Penfill® NovoPen Echo® Plus	87	86	96
Tresiba®Penfill® NovoPen Echo® Plus	90	89	99

## 7.13 Plastic footprint NovoPen Echo® Plus

The plastic footprint is defined by Novo Nordisk as the amount of plastic<sup>15</sup> used by a patient or an organisation during a specific treatment. The footprint includes any plastic placed on the market by Novo Nordisk, regardless of its origin (virgin, recycled, fossil or non-fossil). The footprint is calculated both with and without secondary and tertiary packaging.

This section presents the plastic footprint for specific treatments (assumptions described in Section 2) with NovoPen Echo® Plus in combinations with a range on drug substances (delivered in Penfill®) and needles in the three representative markets, Europe, US and Japan. The contribution to the plastic footprints from the delivery system, cartridge, needle and packaging are shown as well as the total plastic footprint per patient per year.

Table 56 Plastic footprint for the delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for yearly treatment with *NovoPen Echo® Plus* combined with NovoFine® with and without packaging. The softcase for the NovoPen is included in “device”.

Brand name	NovoPen Echo® Plus [g plastic/year]		Penfill® [g plastic/year]		NovoFine® [g plastic/year]		One year treatment [kg plastic/year]	
	Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
	All	EU/US	All	EU/US	All	EU/US	All	EU/US
<b>Actrapid®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	394	2	0.43	0.48
<b>Fiasp®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	394	2	0.43	0.48
<b>Insulatard®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	394	2	0.43	0.48
<b>Levemir®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	394	2	0.43	0.48
<b>Mixtard®Penfil® NovoPen Echo® Plus</b>	17	0.3	15	50	394	2	0.43	0.48
<b>NovoMix®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	394	2	0.43	0.48
<b>NovoRapid®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	394	2	0.43	0.48
<b>Ryzodeg®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	394	2	0.43	0.48

<sup>15</sup> Rubber not included

Brand name	NovoPen Echo® Plus [g plastic/year]		Penfill® [g plastic/year]		NovoFine® [g plastic/year]		One year treatment [kg plastic/year]	
	Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
	All	EU/US	All	EU/US	All	EU/US	All	EU/US
<b>Tresiba®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	394	2	0.43	0.48

Table 57. Plastic footprint for the delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for yearly treatment with *NovoPen Echo® Plus* combined with NovoFine® Plus with and without packaging.

Brand name	NovoPen Echo® Plus [g plastic/year]			Penfill® [g plastic/year]			NovoFine® plus [g plastic/year]			One year treatment [kg plastic/year]		
	Delivery system	Packaging		Cartridge	Packaging		Needle	Packaging		Excl. packaging	Incl. packaging	
	All	EU/US	JP	All	EU/US	JP	All	EU/US	JP	All	EU/US	JP
<b>Actrapid®Penfill® NovoPen Echo® Plus</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Fiasp®Penfill® NovoPen Echo® Plus</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Insulatard®Penfill® NovoPen Echo® Plus</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Levemir®Penfill® NovoPen Echo® Plus</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Mixtard®Penfill® NovoPen Echo® Plus</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>NovoMix®Penfill® NovoPen Echo® Plus</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>NovoRapid®Penfill® NovoPen Echo® Plus</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Ryzodeg®Penfill® NovoPen Echo® Plus</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56
<b>Tresiba®Penfill® NovoPen Echo® Plus</b>	17	0.3	0.3	15	50	100	402	2	28	0.43	0.49	0.56

Table 58. Plastic footprint for the delivery system, cartridge (including primary packaging), needle (including primary packaging) and packaging (secondary and tertiary) required for yearly treatment with *NovoPen Echo® Plus* combined with *NovoFine® Plus* (co-pack) with and without packaging.

Brand name	NovoPen Echo® Plus [g plastic/year]		Penfill® [g plastic/year]		NovoFine® Plus (co-pack) [g plastic/year]		One year treatment [kg plastic/year]	
	Delivery system	Packaging	Cartridge	Packaging	Needle	Packaging	Excl. packaging	Incl. packaging
	All	EU/US	All	EU/US	All	EU/US	All	EU/US
<b>Actrapid®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Fiasp®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Insulatard®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Levemir®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Mixtard®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	402	20	0.43	0.50
<b>NovoMix®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	402	20	0.43	0.50
<b>NovoRapid®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Ryzodeg®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	402	20	0.43	0.50
<b>Tresiba®Penfill® NovoPen Echo® Plus</b>	17	0.3	15	50	402	20	0.43	0.50

## References

Insulin analogues carbon footprint, Novo Nordisk, Mar 2024

Insulin icodec carbon footprint, Novo Nordisk, Jul 2023

NovoPen® carbon footprint, Novo Nordisk, Oct 2024

Penfill® carbon footprint, Novo Nordisk, Dec 2024

NovoFine® carbon footprint, Novo Nordisk, Nov 2024, vs. 3.1

Assumptions and background for carbon footprint assessments, Novo Nordisk, Apr 2025

Novo Nordisk A/S

Novo Allé

DK-2880 Bagsværd

Denmark

Telephone +45 4444 8888

[www.novonordisk.com](http://www.novonordisk.com)